<DOC>
	<DOCNO>NCT01948024</DOCNO>
	<brief_summary>This Multiple-dose , steady state , three-way reference-replicated crossover study . The purpose Study determine bio-equivalence SAPHRIS Asenapine 10mg sublingual tablet .</brief_summary>
	<brief_title>Bio-equivalence Study Between SAPHRIS Asenapine</brief_title>
	<detailed_description>Molecule Name Asenapine Country submission US PRODUCT DETAILS Test formulation Drug name : Asenapine Sublingual Tablet EQ 10mg base Manufactured : Sun Pharmaceutical Industries , Ltd. Reference formulation Drug name : SAPHRIS® ( Asenapine ) sublingual tablet Manufactured : Schering Corporation , Subsidiary Merck &amp; Co. , Inc. STUDY DESIGN Title An open-label , randomize , two treatment , multi-site , multiple dose , steady state , three-way , reference-replicated crossover , pharmacokinetic study determine in-vivo bioequivalence Asenapine 10 mg sublingual tablet SAPHRIS® ( asenapine ) 10 mg sublingual tablet Study Design Multiple-dose , steady state , three-way reference-replicated crossover study Type Study Pharmacokinetic ( PK ) Number subject 57 randomize complete 42 subject Dosing Test Reference drug ( EQ 10mg ) base sublingual tablet take twice daily , morning evening , period 7 day crossing-over receive next drug assign period 7 day , follow period 7 day third drug assign received.. There total three 7-day treatment period subject receive test product one period reference product two period . To ensure optimal absorption , subject instruct place tablet tongue allow dissolve completely . The tablet dissolve saliva . Tablets crush , chew , swallow Housing Subjects house clinic hospital multiple day period treatment collection pharmacokinetic sample . Housing provide : - Day 1 Day 8 15 ( 12-hour confinement ) - Days 6-7 - Days 13-14 - Days 20-21 Investigators may choose house subject interim day specify in-patient clinic visit , either clinic appropriate off-site facility hotel motel . Housing offer may make subject population accord respective Investigator 's judgment best his/her patient . Such interim housing consider study visit , offer discretion Investigator subject his/her clinic , his/her discretion , simply improve subject compliance attempt reduce variability . Subjects confine least 12 hour initial dose either SAPHRIS® ( Asenapine ) Asenapine sublingual tablet . Subjects require remain supine 6 hour follow initial dose . Subjects may get briefly order relieve . Washout period There washout period Sampling time point Blood sample collect dose interval day 7 , follow preliminary sample day 5 6 confirm steady-state condition . The sampling time point follow : - Day 5 ( 1 sample ) - Day 6 ( 1 sample ) - Day 7 ( 15 sample ) 0.0 ( pre-dose ) , 0.25 , 0.5 , 1.0 , 1.5 , 2.0 , 2.5 , 3.0 , 3.5 , 4.0 , 5.0 , 6.0 , 8.0 , 10.0 , 12.0 Dietary Plan Subjects fast least 8 hour prior 4 hour administration morning dose test reference treatment day 7 period ( i.e. , day blood sample collect assess concentration-time curve ) . All meal day 7 standardize study . Water may allow , except 1 hour 1 hour drug administration , liquid permit . Special requirement - Subjects remain supine position first 6 hour first dose , even previously stable dose asenapine maleate . - Subjects adequately hydrate . This may achieve administer 240 mL water overnight fast , 240 mL water one hour dosing , begin sooner 1 hour drug administration , 240 mL water every 2 hour 6 hour post-dosing . Subjects eat drink 10 minute drug administration . - Subjects must adequately inform possible cardiovascular adverse effect consent form . Safety Parameters - White blood cell ( WBC ) count monitored asenapine maleate sublingual tablet treatment modify , necessary , accordance leukopenia , neutropenia agranulocytosis warn label reference list drug product . - Subjects require modification asenapine maleate sublingual tablet treatment drop study provide prompt medical care . - Blood pressure , heart rate , body temperature monitor study immediate medical care provide significant abnormality . - Subject medical history , physical examination laboratory report , incident possible adverse reaction report . Analyte ( ) measure Asenapine plasma Pharmacokinetic parameter Asenapine AUC0-tau , Cmax , Tmax , Cmin % Fluctuation estimate subject period use WinNonlin version 5.2 high . The trough sample collect prior morning dose Days 5 , 6 7 period evaluate demonstrate steady-state achieve final morning dose period . Statistical Analysis The primary pharmacokinetic parameter ( Cmax , AUC0-tau , ) Cmin natural log-transformed ( ln ) prior statistical analysis . Any ln-transformed parameter observe intra-subject CV reference product least 30 % ( swr ≥ 0.294 ) evaluate use scaled average bioequivalence ( SABE ) method . The GLM procedure SAS use conduct SABE analyse , well estimate intra-subject CV reference product . The statistical model GLM procedure contain term Sequence*Site . The linearized Scaled Average Bioequivalence statistic upper 95 % Confidence Bound statistic estimate . The ratio geometric mean ( T/R ) also calculate . Plasma concentration time point , Tmax , % Fluctuation , ln-transformed pharmacokinetic parameter observe intra-subject CV reference product le 30 % ( swr &lt; 0.294 ) , evaluate use average ( unscaled ) bioequivalence ( ABE ) approach use . The MIXED procedure SAS use case statistical model include term Sequence , Site , Sequence*Site , Subject nest within Sequence*Site , Period nest within Site , Treatment , necessary , Treatment*Site . A separate statistical analysis do determine Treatment*Site term statistically significant ( p &lt; 0.05 ) need retain model . If term significant , drop statistical model definitive statistical evaluation . The ratio geometric mean ( T/R ) 90 % confidence interval ratio , base least-squares mean analysis log-transformed PK Parameter , calculate . Bioequivalence criterion Bioequivalence conclude primary parameter evaluate SABE : - The geometric mean Test-to-Reference ratio fall within range 0.800 1.250 . - The 95 % upper confidence bound linearize SABE statistic . Bioequivalence conclude primary parameter evaluate ABE : The 90 % confidence interval geometric mean Test-to Reference ratio contain within interval 0.800 1.250 . Fluctuation test product evaluate comparability fluctuation reference product . Report format eCTD</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>1 . Male and/or nonpregnant female subject age 18 80 year age 2 . For female childbearing potential , subject must willing practice clinically accept method birth control 3 . Receiving stable twice daily dose Asenapine Maleate EQ 10 mg base sublingual tablet least 3 month prior randomization 4 . Subjects otherwise healthy determine investigator reference physical examination , medical history routine hematologic biochemical test 5 . Able obtain write informed consent study subject Subject 's Legally Acceptable Representative ( LAR ) . If subject his/her LAR unable read/write , impartial witness present entire consenting process must append his/her signature consent form 1 . A history clinically significant allergic adverse reaction asenapine maleate comparable similar product 2 . QTc &gt; 450 msec male subject QTc &gt; 470 msec female subject screen 3 . Heart rate screen less 50 bts/min 4 . Hypokalemia ( define serum plasma potassium le 3.5 mM mEq/L ) and/or Hypomagnesaemia ( define serum magnesium le 0.7 mEq/L ) screening . 5 . A history severe hepatic impairment , drug induce leukopenia/neutropenia , congenital prolongation QT interval , cardiac arrhythmia , myocardial infarction unstable heart disease 6 . Concurrent primary psychiatric neurological diagnosis , include organic mental disorder , severe tardive dyskinesia , idiopathic Parkinson 's disease 7 . A total white blood cell count 4000/mL , absolute neutrophil count 2000/mL 8 . A history granulocytopenia myeloproliferative disorder ( druginduced idiopathic ) 9 . Significant orthostatic hypotension ( i.e. , drop systolic blood pressure 30 mm Hg and/or drop diastolic blood pressure 20 mm Hg standing ) 10 . Concurrent use antihypertensive medication medication predispose orthostatic hypotension , unless receive stable dose medication least 3 month prior randomization . 11 . A medical surgical condition might interfere absorption , metabolism , excretion Asenapine 12 . A history epilepsy risk seizures 13 . Concurrent use drug know suppress bone marrow function 14 . Expected change concomitant medication period study 15 . Positive test drug alcohol abuse screen baseline 16 . A history alcohol drug dependence Diagnostic Statistical Manual Mental Disorders IV ( DSMIV ) criteria 6month period immediately prior study entry 17 . Has participate another clinical research study within 30 day prior randomization 18 . Compliance outpatient medication schedule expect 19 . History multiple syncopal episode 20 . Any clinically significant condition investigator think put subject risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>